RU2605307C2 - Гуманизированные антитела к сd52 - Google Patents

Гуманизированные антитела к сd52 Download PDF

Info

Publication number
RU2605307C2
RU2605307C2 RU2013158454/10A RU2013158454A RU2605307C2 RU 2605307 C2 RU2605307 C2 RU 2605307C2 RU 2013158454/10 A RU2013158454/10 A RU 2013158454/10A RU 2013158454 A RU2013158454 A RU 2013158454A RU 2605307 C2 RU2605307 C2 RU 2605307C2
Authority
RU
Russia
Prior art keywords
human
antibody
cells
antibodies
seq
Prior art date
Application number
RU2013158454/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2013158454A (ru
Inventor
Тимоти Дэвид ДЖОНС
Роберт Джордж Эдвард ХОЛГЕЙТ
Френсис Джозеф КАРР
Original Assignee
Антитоуп Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Антитоуп Лтд filed Critical Антитоуп Лтд
Publication of RU2013158454A publication Critical patent/RU2013158454A/ru
Application granted granted Critical
Publication of RU2605307C2 publication Critical patent/RU2605307C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
RU2013158454/10A 2011-06-01 2012-06-01 Гуманизированные антитела к сd52 RU2605307C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161492005P 2011-06-01 2011-06-01
US61/492,005 2011-06-01
GB1109238.4 2011-06-01
GBGB1109238.4A GB201109238D0 (en) 2011-06-01 2011-06-01 Antibodies
PCT/EP2012/060345 WO2012164063A1 (en) 2011-06-01 2012-06-01 Humanised anti-cd52 antibodies

Publications (2)

Publication Number Publication Date
RU2013158454A RU2013158454A (ru) 2015-07-20
RU2605307C2 true RU2605307C2 (ru) 2016-12-20

Family

ID=44310746

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013158454/10A RU2605307C2 (ru) 2011-06-01 2012-06-01 Гуманизированные антитела к сd52

Country Status (16)

Country Link
US (1) US9321841B2 (enExample)
EP (1) EP2714739A1 (enExample)
JP (1) JP6254522B2 (enExample)
KR (1) KR20140036274A (enExample)
CN (1) CN103649122B (enExample)
AU (1) AU2012264643B2 (enExample)
BR (1) BR112013030875A2 (enExample)
CA (1) CA2837965A1 (enExample)
GB (1) GB201109238D0 (enExample)
IL (1) IL229713A (enExample)
MX (1) MX342676B (enExample)
MY (1) MY163257A (enExample)
RU (1) RU2605307C2 (enExample)
SG (1) SG195042A1 (enExample)
WO (1) WO2012164063A1 (enExample)
ZA (1) ZA201308900B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012047A (es) 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
CN106018814B (zh) * 2016-08-07 2017-11-14 深圳市南海生物科技有限公司 一种用于白血病和自身免疫病检测用试剂盒
TW201841653A (zh) * 2017-04-21 2018-12-01 美商建新公司 以抗-cd52抗體治療多發性硬化症
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
CN117534750B (zh) * 2023-10-16 2024-06-11 遵义医科大学珠海校区 一种抗新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1508155A (zh) * 2002-12-18 2004-06-30 菁 马 抗cd52单克隆抗体、其编码序列及应用
WO2005042581A2 (en) * 2003-11-01 2005-05-12 Biovation Ltd. Modified anti-cd52 antibody
RU2007147414A (ru) * 2005-05-24 2009-07-10 Эйвестаджен Лимитед,In (In) Способ рекомбинантного получения моноклонального антитела к cd52, предназначенного для лечения хронического лимфолейкоза
WO2010132659A2 (en) * 2009-05-13 2010-11-18 Genzyme Corporation Anti-human cd52 immunoglobulins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
JP4334866B2 (ja) * 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
CA2832136C (en) * 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
WO2005062893A2 (en) * 2003-12-22 2005-07-14 Genzyme Corporation Anti-cd52 antibody treatment for diabetes
CA2596833C (en) 2005-02-03 2016-04-12 Antitope Limited Human antibodies and proteins
CN102079787A (zh) * 2010-12-09 2011-06-01 协和干细胞基因工程有限公司 抗人cd52的工程抗体、载体、试剂盒及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1508155A (zh) * 2002-12-18 2004-06-30 菁 马 抗cd52单克隆抗体、其编码序列及应用
WO2005042581A2 (en) * 2003-11-01 2005-05-12 Biovation Ltd. Modified anti-cd52 antibody
RU2007147414A (ru) * 2005-05-24 2009-07-10 Эйвестаджен Лимитед,In (In) Способ рекомбинантного получения моноклонального антитела к cd52, предназначенного для лечения хронического лимфолейкоза
WO2010132659A2 (en) * 2009-05-13 2010-11-18 Genzyme Corporation Anti-human cd52 immunoglobulins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ENBLAD G. et al., A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas, BLOOD, 2004, vol.103, no.8, pp.2920-2924. *

Also Published As

Publication number Publication date
IL229713A (en) 2017-03-30
MX342676B (es) 2016-10-07
JP6254522B2 (ja) 2017-12-27
AU2012264643A1 (en) 2013-12-19
CA2837965A1 (en) 2012-12-06
US20140127236A1 (en) 2014-05-08
WO2012164063A1 (en) 2012-12-06
JP2014518630A (ja) 2014-08-07
EP2714739A1 (en) 2014-04-09
CN103649122B (zh) 2017-09-05
KR20140036274A (ko) 2014-03-25
SG195042A1 (en) 2013-12-30
RU2013158454A (ru) 2015-07-20
ZA201308900B (en) 2015-02-25
AU2012264643B2 (en) 2016-09-29
CN103649122A (zh) 2014-03-19
US9321841B2 (en) 2016-04-26
MX2013014083A (es) 2014-09-16
IL229713A0 (en) 2014-01-30
BR112013030875A2 (pt) 2016-11-29
GB201109238D0 (en) 2011-07-13
MY163257A (en) 2017-08-30

Similar Documents

Publication Publication Date Title
JP6254522B2 (ja) ヒト化抗ｃｄ５２抗体
JP6211930B2 (ja) ヒト化抗ｃｔｌａ４抗体
US8337842B2 (en) Monoclonal antibodies
AU2019452936B2 (en) Bispecific antibody, preparation method therefor and application thereof
CA2791866A1 (en) Monoclonal antibodies directed to cd52
KR20220137723A (ko) 항-cd3 및 항-cd123 이중 특이성 항체 및 이의 용도
JP2023539654A (ja) 抗ｏｘ４０抗体、その医薬組成物および応用
CN114269788B (zh) 一种能够与人4-1bb结合的分子及其应用
EP3781203A1 (en) Anti-cd40 antibodies and uses thereof
AU2014200771B2 (en) Monoclonal antibodies
AU2016216708A1 (en) Monoclonal antibodies
AU2009288700B2 (en) Monoclonal antibodies
EA051475B1 (ru) Антитела к cd122 и их применение
HK1213910B (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
PD4A Correction of name of patent owner
PC41 Official registration of the transfer of exclusive right

Effective date: 20220225